---
title: "Weekly Recap | Karyopharm Therap -91.71%, Chapter 11 filing"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/304722888.md"
description: "Karyopharm (KPTI) dropped 91.71% this week to close at $0.0549, versus a 2.68% decline for the S&P 500, underperforming the benchmark by roughly 89.03 percentage points. The move was a one-way slide: Monday opened at $0.1530, mid-week fell to a weekly low of $0.0729 on Wednesday, and Friday’s session saw an intraday trough of $0.0401 before settling slightly higher. Weekly amplitude came to 78.37%."
datetime: "2026-11-07T08:15:38.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/304722888.md)
  - [en](https://longbridge.com/en/news/304722888.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/304722888.md)
generator: "portal-rs"
---

# Weekly Recap | Karyopharm Therap -91.71%, Chapter 11 filing

## The Week

Karyopharm (KPTI) dropped 91.71% this week to close at $0.0549, versus a 2.68% decline for the S&P 500, underperforming the benchmark by roughly 89.03 percentage points. The move was a one-way slide: Monday opened at $0.1530, mid-week fell to a weekly low of $0.0729 on Wednesday, and Friday’s session saw an intraday trough of $0.0401 before settling slightly higher. Weekly amplitude came to 78.37%.

## Key Events

The central story is the company’s Chapter 11 filing and its prepackaged restructuring with Ayrmid Ltd. The merger plan was announced Monday, followed by a 55% premarket drop; by Wednesday lenders had unanimously supported the prepackaged Chapter 11 plan. In parallel, Karyopharm reported sustained benefit through 48 weeks in the Phase 3 selinexor myelofibrosis trial, which triggered intermittent rebounds against the prevailing sell-off. The narrative this week ran on legal process and Phase 3 data rather than a fresh deterioration in operating fundamentals.

## Analyst Ratings

Of the 5 brokers covering the name, 2 rate it strong buy, 2 rate it buy and 1 rates it hold; none rate it under or sell. The consensus rating is buy. The consensus target of $7.25 sits far above the latest price, implying a ~13,105.83% upside; individual targets range from $3.00 to $11.00, with dispersion centred on how much residual value post-reorganisation can survive until clinical data read through. The stock ranks 286th among 510 companies in the biotechnology industry.

## The Week Ahead

The macro focus next week is CPI: on Tuesday 10 November, headline and core CPI prints are due, with headline CPI seen edging up to 3.9% year-on-year from 3.7% and core CPI at 2.8%. For KPTI, the more pressing items are the pace of restructuring and any follow-up to the Nasdaq delisting notice already issued, including whether the company will appeal or clarify its next steps.

## In Short

Ratings sit at a buy consensus with an enormous gap between target and spot, but that gap itself signals a disconnect between broker models and how the market is pricing post-reorganisation equity. The latest trading day showed net buying by retail and mid-lot money while large-lot flow was limited. The real question ahead is not whether the stock can return to clinical-data-implied valuation, but whether the Chapter 11 process can preserve existing equity from being wiped out or heavily diluted.

*This article is generated by LongbridgeAI from market data, for information only and not investment advice.*

### Related Stocks

- [KPTI.US](https://longbridge.com/en/quote/KPTI.US.md)
- [KPTIQ.US](https://longbridge.com/en/quote/KPTIQ.US.md)

## Related News & Research

- [Karyopharm reports sustained benefit through 48 weeks in Phase 3 selinexor myelofibrosis trial](https://longbridge.com/en/news/304290863.md)
- [BUZZ-Karyopharm tumbles after bankruptcy filing, merger plan with Ayrmid](https://longbridge.com/en/news/303968036.md)
- [Karyopharm extends noteholder forbearance period to Oct. 22](https://longbridge.com/en/news/301835273.md)
- [Credo Technology Stock Is Surging Wednesday: What's Going On?](https://longbridge.com/en/news/305155753.md)
- [Is the Stock Market Going to Crash? Warren Buffett's Warning Is Hard to Ignore.](https://longbridge.com/en/news/305154637.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**